Health and Healthcare
Arena Pharmaceuticals Sinks After Announcing Secondary Offering
Published:
Last Updated:
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) saw its shares drop sharply on Tuesday after the company announced a secondary offering. Arena plans to offer 60 million shares of its common stock at the price of $1.15 per share, with an overallotment option for an additional 9 million shares. At this price, the entire offering is valued up to roughly $79.35 million.
The underwriters for the offering are Citigroup and Leerink Partners.
This biopharmaceutical company is focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas.
Three of its most advanced investigational clinical programs are ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension, etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune indications, and APD371 in Phase 2 evaluation for the treatment of pain associated with Crohn’s disease.
Additionally, it has collaborations with Eisai, Axovant Sciences and Boehringer Ingelheim International.
The company intends to use the net proceeds from this offering for the clinical and preclinical development of drug candidates; for general corporate purposes, including working capital and costs associated with manufacturing services; and for capital expenditures.
At the end of March 2017, the company had roughly $79.5 million of cash and cash equivalents. Overall its market cap is $307 million.
Shares of Arena were last seen down 15% at $1.25 on Tuesday, with a consensus analyst price target of $3.75 and a 52-week trading range of $1.21 to $2.16.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
